AIA Group Ltd Has $1.09 Million Stock Holdings in Moderna, Inc. (NASDAQ:MRNA)

AIA Group Ltd grew its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 12.2% during the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 16,291 shares of the company’s stock after buying an additional 1,765 shares during the quarter. AIA Group Ltd’s holdings in Moderna were worth $1,089,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the stock. Janney Montgomery Scott LLC increased its holdings in Moderna by 38.6% in the 1st quarter. Janney Montgomery Scott LLC now owns 14,373 shares of the company’s stock worth $1,532,000 after purchasing an additional 4,003 shares in the last quarter. Empirical Finance LLC increased its stake in shares of Moderna by 4.7% in the first quarter. Empirical Finance LLC now owns 8,975 shares of the company’s stock valued at $956,000 after buying an additional 399 shares during the period. Empowered Funds LLC increased its stake in shares of Moderna by 26.8% in the first quarter. Empowered Funds LLC now owns 4,276 shares of the company’s stock valued at $456,000 after buying an additional 904 shares during the period. SG Americas Securities LLC raised its holdings in Moderna by 32.8% in the 1st quarter. SG Americas Securities LLC now owns 79,310 shares of the company’s stock valued at $8,451,000 after buying an additional 19,609 shares during the last quarter. Finally, Oppenheimer & Co. Inc. boosted its position in Moderna by 25.6% during the 1st quarter. Oppenheimer & Co. Inc. now owns 40,305 shares of the company’s stock worth $4,295,000 after buying an additional 8,214 shares during the period. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the stock. Needham & Company LLC reaffirmed a “hold” rating on shares of Moderna in a research note on Friday. Bank of America decreased their price objective on Moderna from $130.00 to $110.00 and set a “neutral” rating for the company in a report on Friday, September 13th. Barclays cut their target price on Moderna from $125.00 to $111.00 and set an “overweight” rating on the stock in a report on Friday. Deutsche Bank Aktiengesellschaft upgraded Moderna from a “sell” rating to a “hold” rating and lowered their price objective for the stock from $85.00 to $80.00 in a research report on Wednesday, August 7th. Finally, Leerink Partners reduced their target price on Moderna from $60.00 to $48.00 and set an “underperform” rating on the stock in a report on Tuesday, September 17th. Two analysts have rated the stock with a sell rating, fourteen have given a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, Moderna presently has a consensus rating of “Hold” and a consensus price target of $93.18.

Insiders Place Their Bets

In other news, CFO James M. Mock sold 715 shares of the firm’s stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $60.12, for a total value of $42,985.80. Following the transaction, the chief financial officer now owns 9,505 shares in the company, valued at $571,440.60. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other Moderna news, CFO James M. Mock sold 1,321 shares of the company’s stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total value of $104,874.19. Following the completion of the sale, the chief financial officer now directly owns 8,600 shares of the company’s stock, valued at approximately $682,754. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO James M. Mock sold 715 shares of the business’s stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $60.12, for a total value of $42,985.80. Following the completion of the transaction, the chief financial officer now owns 9,505 shares in the company, valued at $571,440.60. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 3,184 shares of company stock valued at $238,531. Corporate insiders own 15.70% of the company’s stock.

Moderna Stock Performance

NASDAQ MRNA opened at $46.83 on Friday. The company has a market cap of $18.00 billion, a P/E ratio of -3.04 and a beta of 1.69. The company has a fifty day simple moving average of $61.85 and a 200 day simple moving average of $99.22. The company has a current ratio of 4.09, a quick ratio of 3.92 and a debt-to-equity ratio of 0.05. Moderna, Inc. has a 12-month low of $46.57 and a 12-month high of $170.47.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings data on Thursday, November 7th. The company reported $0.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.89) by $1.92. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.35%. The firm had revenue of $1.90 billion during the quarter, compared to analysts’ expectations of $1.25 billion. During the same period last year, the company earned ($1.39) earnings per share. The business’s revenue was up 3.8% on a year-over-year basis. Sell-side analysts predict that Moderna, Inc. will post -9.89 earnings per share for the current fiscal year.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.